Back to top

Analyst Blog

The share price of Alnylam Pharmaceuticals, Inc. (ALNY - Analyst Report) shot up around 10.2% on Sep 23, 2013 to close the trading session at $63.05. The stock was buoyed by the positive interim results from a phase I study on its pipeline candidate ALN-TTRsc. Alnylam also touched a 52-week high of $63.84 on Sep 23.

ALN-TTRsc is a sub cutaneous ribo nucleic acid interference (RNAi) therapeutic targeting the transthyretin (TTR) gene that is being developed for the treatment of TTR-mediated amyloidosis (ATTR). Results from the study revealed that ALN-TTRsc was successful in robust, consistent, and statistically significant reduction in serum TTR protein levels up to 94% in healthy volunteers enrolled in the study.

Interim results also revealed that ALN-TTRsc was generally safe and well tolerated in the study. Moreover, no serious adverse effects were found during the study.

Alnylam mentioned in its press release that it is on track to initiate a pilot phase II study on ALN-TTRsc in patients suffering from familial amyloidotic cardiomyopathy (FAC) by year end. Positive results from the phase II study will allow the company to initiate a phase III study on the candidate by the end next year.

We remind investors that Alnylam also has ALN-TTR02 in its pipeline that is being developed for the treatment of ATTR patients with FAP. Alnylam is currently evaluating the safety and tolerability of the candidate in a phase II study. The company plans to initiate a phase III study on the candidate in polyneuropathy patients by Dec 31, 2013.

We note that Alnylam has a development and commercialization agreement with Sanofi (SNY - Analyst Report) for Alnylam’s RNAi therapeutics, which include ALN-TTR02 and ALN-TTRsc. The agreement is for the development and commercialization of these candidates in Japan and the broader Asian-Pacific region. Alnylam intends to develop and commercialize the ALN-TTR program in other countries as well.

We are encouraged by the positive results from the phase I study. Alnylam has progressed well so far with its RNAi therapeutics candidates. However, most of the candidates at the company’s pipeline are in the early or middle stages of development. We expect investor focus to remain on Alnylam’s pipeline going forward.

Alnylam presently carries a Zacks Rank #3 (Hold). Stocks such as Biogen Idec Inc. (BIIB - Analyst Report) and Actelion Ltd. (ALIOF) currently look better positioned with a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
TRIQUINT SE… TQNT 20.65 +6.44%
RF MICRO DE… RFMD 12.45 +5.87%
VASCO DATA… VDSI 14.82 +5.03%
STRATTEC SE… STRT 80.77 +3.68%
PATTERSON-U… PTEN 34.53 +2.94%